Digital application to improve sexual health for stem cell transplant survivors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research evaluates a novel self-administered digital application designed to enhance sexual health outcomes, quality of life, and reduce psychological distress in survivors of hematopoietic stem cell transplants. The study addresses the significant sexual dysfunction experienced by these patients, which is a common long-term complication following treatment. By utilizing a multimodal approach, the intervention aims to empower survivors to communicate their sexual health concerns with their clinicians, thereby improving their overall well-being. Participants will be divided into two groups: one receiving the SHIFT intervention and the other receiving enhanced usual care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients (\> 18 years) who underwent autologous or allogeneic HCT \> three months prior to study enrollment
* Screen positive for sexual health concerns causing distress based on the National Comprehensive Network (NCCN) survivorship guidelines screening questions

Exclusion Criteria:

* Patients who do not comprehend English or Spanish since SHIFT will only be available in these two languages for this efficacy trial.
* Patients with any major uncontrolled psychiatric disorder or other comorbid cognitive conditions, which the treating HCT clinician believes would prohibit the patients' capacity to provide informed consent and participate in study procedures.
* Patients with relapsed disease requiring treatment.

Where it's running

• Massachusetts General Hospital (MGH)
  Boston, Massachusetts, United States Recruiting
• University of Miami
  Coral Gables, Florida, United States Not yet recruiting
• Fox Chase Cancer Center
  Philadelphia, Pennsylvania, United States Not yet recruiting

Study contacts

• Study coordinator: Areej El-Jawahri, MD
• Email: ael-jawahri@mgb.org
• Phone: 617-724-4000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PRP injection for female sexual function

  This trial tests whether a patient’s own PRP injection into the front vaginal wall can improve sexual function in women with sexual dysfunction.

  Recruiting Icahn School of Medicine at Mount Sinai · New York, New York · NCT07920900

• What predicts religious orientation attitudes in menopausal women

  This study tests whether how severe menopausal symptoms and beliefs about sexual myths relate to intrinsic religious orientation in healthy women going through menopause.

  Recruiting KTO Karatay University · Konya · NCT07797296

• Sexual function and quality of life in monogamous vs polygamous marriages among Egyptian men

  This is a web-based survey to see if marital structure affects erectile function and sexual quality of life in Egyptian men who are married.

  Recruiting Al-Azhar University · Cairo · NCT07783958

• Combining ruxolitinib with corticosteroids for severe acute graft‑versus‑host disease

  This trial tests whether adding ruxolitinib to corticosteroids as first‑line treatment helps people who develop severe acute graft‑versus‑host disease after a first stem cell transplant.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07509749

• Venetoclax added to reduced-intensity conditioning for combined stem cell and kidney transplant

  This trial tests whether adding venetoclax to a reduced-intensity conditioning regimen is safe for adults with blood cancers who are receiving a combined stem cell and kidney transplant from a matched or partially matched donor.

  Recruiting Early Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT07358195

• First-line ruxolitinib plus corticosteroids for grade II acute graft-versus-host disease

  This trial will test whether adding ruxolitinib to standard corticosteroids helps people with new grade II acute graft-versus-host disease after an allogeneic stem cell transplant.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07340723

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.